10-Q 1 form_10-q.htm FORM 10-Q FOR Q2 2014 form_10-q.htm



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
þ
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

OR

o
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number: 000-53252

 
WaferGen Bio-systems, Inc.
 
 
(Exact Name of Registrant as Specified in its Charter)
 

 
Nevada
 
90-0416683
 
 
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)
 

 
7400 Paseo Padre Parkway, Fremont, CA
 
94555
 
 
(Address of principal executive offices)
 
(Zip Code)
 

 
(510) 651-4450
 
 
(Registrant’s telephone number, including area code)
 


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ   No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ   No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer ¨  (Do not check if a smaller reporting company)
Smaller reporting company þ

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o   No þ

The Registrant had 937,719 shares of common stock outstanding as of August 12, 2014.







 
 

 


TABLE OF CONTENTS


   
Page
Part I
FINANCIAL INFORMATION
 
         
   
         
     
         
     
         
     
         
     
         
   
         
   
         
         
Part II
OTHER INFORMATION
 
         
   
         
   
         
   
         
 
     
 




 

PART I FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited)

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

   
June 30, 2014
   
December 31, 2013
 
Assets
 
(Unaudited)
       
Current assets:
           
Cash and cash equivalents
  $ 3,521,549     $ 10,708,646  
Accounts receivable
    1,622,301       367,266  
Inventories
    839,808       292,650  
Prepaid expenses and other current assets
    417,033       350,540  
                 
Total current assets
    6,400,691       11,719,102  
                 
Property and equipment, net
    368,488       269,618  
Goodwill
    990,000        
Intangible assets, net
    1,611,000        
Other assets
    42,209       42,209  
                 
Total assets
  $ 9,412,388     $ 12,030,929  
                 
Liabilities and Stockholders’ Equity (Deficit)
               
Current liabilities:
               
Accounts payable
  $ 1,798,746     $ 980,887  
Accrued payroll and related costs
    467,527       289,053  
Other current liabilities
    903,392       1,143,335  
                 
Total current liabilities
    3,169,665       2,413,275  
                 
Long-term debt, net of discount
    2,996,424       1,683,942  
Derivative liabilities
    952,172       9,147,507  
Other liabilities
    576,276        
                 
Total liabilities
    7,694,537       13,244,724  
                 
Commitments and contingencies (Note 14)
    ––       ––  
                 
Stockholders’ equity (deficit):
               
Preferred Stock: $0.001 par value; 10,000,000 shares authorized; 2,870.2887 and 2,944.7080 shares of Series 1 Convertible Preferred Stock issued and outstanding at June 30, 2014 and December 31, 2013
    13,252,070       13,595,662  
Common Stock: $0.001 par value; 300,000,000 shares authorized; 937,719 and 911,256 shares issued and outstanding at June 30, 2014 and December 31, 2013
    73,952,977       66,028,712  
Accumulated deficit
    (85,487,196 )     (80,838,169 )
                 
Total stockholders’ equity (deficit)
    1,717,851       (1,213,795 )
                 
Total liabilities and stockholders’ equity (deficit)
  $ 9,412,388     $ 12,030,929  


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


 
1

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES



Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)


   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2014
   
2013
   
2014
   
2013
 
                         
Revenue:
                       
Product
  $ 1,608,908     $ 121,248     $ 2,889,421     $ 216,402  
License and royalty
    125,000       125,000       250,000       208,333  
                                 
Total revenue
    1,733,908       246,248       3,139,421       424,735  
                                 
Cost of product revenue
    758,408       76,780       1,364,981       142,368  
                                 
Gross profit
    975,500       169,468       1,774,440       282,367  
                                 
Operating expenses:
                               
Sales and marketing
    1,364,200       609,296       2,636,989       951,927  
Research and development
    1,472,886       1,263,267       2,839,883       2,665,347  
General and administrative
    1,289,508       564,770       2,101,043       1,225,418  
                                 
Total operating expenses
    4,126,594       2,437,333       7,577,915       4,842,692  
                                 
Operating loss
    (3,151,094 )     (2,267,865 )     (5,803,475 )     (4,560,325 )
                                 
Other income and (expenses):
                               
Interest income
    19       892       27       2,087  
Interest expense
    (109,155 )     (1,092,091 )     (212,482 )     (1,972,629 )
Gain (loss) on revaluation of derivative liabilities, net
    1,158,240       115,237       1,374,196       (478,480 )
Miscellaneous income (expense)
    (1,422 )     79,621       (4,193 )     67,343  
                                 
Total other income and (expenses)
    1,047,682       (896,341 )     1,157,548       (2,381,679 )
                                 
Net loss before provision for income taxes
    (2,103,412 )     (3,164,206 )     (4,645,927 )     (6,942,004 )
                                 
Provision for income taxes
          (1,051 )     3,100       2,661  
                                 
Net loss
    (2,103,412 )     (3,163,155 )     (4,649,027 )     (6,944,665 )
                                 
Accretion on Series A and B convertible preference shares of subsidiary associated with premium
          (2,489,899 )           (2,489,899 )
Series A-1 preferred dividend
          (209,268 )           (415,952 )
                                 
Net loss attributable to common stockholders
  $ (2,103,412 )   $ (5,862,322 )   $ (4,649,027 )   $ (9,850,516 )
                                 
Net loss per share – basic and diluted
  $ (2.28 )   $ (139.79 )   $ (5.07 )   $ (234.89 )
                                 
Shares used to compute net loss per share – basic and diluted
    921,762       41,937       916,588       41,937  
                                 
                                 
                                 
Comprehensive Loss:
                               
                                 
Net loss
  $ (2,103,412 )   $ (3,163,155 )   $ (4,649,027 )   $ (6,944,665 )
                                 
Foreign currency translation adjustments
          (85,571 )           (98,050 )
                                 
Total comprehensive loss
  $ (2,103,412 )   $ (3,248,726 )   $ (4,649,027 )   $ (7,042,715 )


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


 
2

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES



Condensed Consolidated Statements of Cash Flows (Unaudited)


   
Six Months Ended June 30,
 
   
2014
   
2013
 
             
Cash flows from operating activities:
           
Net loss
  $ (4,649,027 )   $ (6,944,665 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation and amortization
    435,952       409,777  
Stock-based compensation
    759,534       182,785  
(Gain) loss on revaluation of derivative liabilities, net
    (1,374,196 )     478,480  
Interest converted to principal on convertible promissory notes
    48,611       416,009  
Provision for excess and obsolete inventory
    (645,886 )     15,717  
Amortization of debt discount
    163,871       1,462,145  
Change in operating assets and liabilities:
               
Accounts receivable
    (1,255,035 )     273,182  
Inventories
    659,934       (37,275 )
Prepaid expenses and other assets
    (66,493 )     (43,629 )
Accounts payable
    817,859       161,707  
Accrued payroll and related costs
    114,474       54,095  
Other accrued expenses
    (73,667 )     409,922  
                 
Net cash used in operating activities
    (5,064,069 )     (3,161,750 )
                 
Cash flows from investing activities:
               
Purchase of property and equipment
    (123,028 )     (34,347 )
Acquisition of business
    (2,000,000 )      
                 
Net cash used in investing activities
    (2,123,028 )     (34,347 )
                 
Effect of exchange rates on cash
          (96,658 )
                 
Net decrease in cash and cash equivalents
    (7,187,097 )     (3,292,755 )
                 
Cash and cash equivalents at beginning of the period
    10,708,646       6,328,753  
                 
Cash and cash equivalents at end of the period
  $ 3,521,549     $ 3,035,998  
                 
                 
Supplemental disclosures of cash flow information:
               
Cash paid for interest
  $     $ 4,341  
Cash paid for income taxes
  $ 3,100     $ 18,582  
Cash (received) for income taxes
  $     $ (1,051 )
                 
                 
Supplemental disclosure of non-cash investing and financing activities:
               
Issuance of promissory note, net of debt discount, in business acquisition
  $ 1,100,000     $  
Initial valuation of revenue earn-out contingency in business acquisition
  $ 410,000     $  
Warrant derivative liabilities transferred to equity on waiver of potential cash settlement provisions
  $ 6,821,139     $  
Inventory transferred to property and equipment
  $ 44,794     $  


The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


 
3

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



NOTE 1.  The Company

General – WaferGen Bio-systems, Inc. and its subsidiaries (the “Company”) are engaged in the development, manufacture and sales of systems for gene expression quantification, genotyping and stem cell research. The Company’s products are aimed at researchers who perform genetic analysis, primarily at pharmaceutical and biotech companies, academic and private research centers and diagnostics companies involved in biomarker discovery and genetic research. Through its SmartChip and Apollo product lines, the Company plans to provide new performance standards with significant savings in time and cost for professionals in the field of gene expression research and to facilitate biomarker discovery, toxicology, and clinical research.

Wafergen, Inc. was incorporated in the State of Delaware on October 22, 2002, and was acquired by WaferGen Bio-systems, Inc. in a reverse merger on May 31, 2007.

On January 24, 2008, the Company formed a subsidiary, WaferGen Biosystems (M) Sdn. Bhd. (“WGBM”), in Malaysia. Prior to WGBM’s liquidation on November 26, 2013, the Company owned 100% of the common stock and 17.2% (comprising shares that had been assumed by the Company) of the preference shares of this entity, with the remaining preference shares owned by Malaysian Technology Development Corporation Sdn. Bhd. (“MTDC”). See Notes 6 and 7 below.

On August 30, 2011, the Company formed a new wholly owned subsidiary in Luxembourg, WaferGen Biosystems Europe S.a.r.l., to establish a presence for its marketing and research activities in Europe.

On August 27, 2013, the Company effected a reverse stock split of its common stock by a ratio of one-for-99.39 (the “2013 Reverse Split”). Every 99.39 outstanding shares of common stock became one share of common stock. No fractional shares were issued in connection with the 2013 Reverse Split. Stockholders who were otherwise entitled to receive a fractional share of common stock received one whole share of common stock. The 2013 Reverse Split did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company’s common or preferred stock.

On June 30, 2014, the Company effected a reverse stock split of its common stock by a ratio of one-for-ten (the “2014 Reverse Split”). Every ten outstanding shares of common stock became one share of common stock. No fractional shares were issued in connection with the 2014 Reverse Split. Stockholders who were otherwise entitled to receive a fractional share of common stock received one whole share of common stock. The 2014 Reverse Split did not change the number of shares of common or preferred stock that the Company is authorized to issue, or the par value of the Company’s common or preferred stock.

The 2013 Reverse Split and the 2014 Reverse Split resulted in a proportionate adjustment to the per share exercise price and the number of shares of common stock issuable upon the exercise of outstanding warrants and stock options, as well as the number of shares of common stock eligible for issuance under the 2008 Stock Incentive Plan. All of the information in these financial statements has been presented to reflect the combined impact of the one-for-99.39 2013 Reverse Split and the one-for-ten 2014 Reverse Split on a retroactive basis.

On January 6, 2014, the Company acquired substantially all of the assets of the product line of IntegenX Inc.  (“IntegenX”) used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for next generation sequencing (“NGS”), including the Apollo 324TM instrument and the PrepXTM reagents (the “Apollo Business”). See Note 3 below.

Management’s Plan.  The Company has incurred operating losses and negative cash flows from operations since its inception. Management expects that revenues will increase as a result of current and future product releases. However, the Company also expects to incur additional expenses for the development and expansion of its products, marketing campaigns, and operating costs as it expands its operations. Therefore, the Company expects operating losses and negative cash flows to continue for the foreseeable future. It is management’s plan to obtain additional working capital through additional financings. The Company believes that it will be successful in expanding operations, gaining market share, and raising additional funds. However, there can be no assurance that in the event the Company requires additional financing, such financing will be available at terms which are favorable, or at all. Failure to generate sufficient cash flows from operations or raise additional capital could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern.


 
4

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



Going Concern.  The Company’s condensed consolidated financial statements have been presented on a basis that contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company continues to face significant risks associated with the successful execution of its strategy given the current market environment for similar companies and failure to generate sufficient revenues or raise additional capital could have a material adverse effect on the Company’s ability to continue as a going concern and to achieve its intended business objectives. These facts raise substantial doubt about the Company’s ability to continue as a going concern, and there can be no assurance that the Company will be successful in its efforts to enhance its liquidity situation. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.


NOTE 2.  Summary of Significant Accounting Policies

Basis of Presentation – The Company has prepared the accompanying condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to these rules and regulations. These condensed consolidated financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2013, included in our Form 10-K filed with the SEC. In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the Company’s financial position and the results of its operations and cash flows. The results of operations for such interim periods are not necessarily indicative of the results to be expected for the full year.

Basis of Consolidation – The condensed consolidated financial statements include the financial statements of WaferGen Bio-systems, Inc. and its subsidiaries. All significant transactions and balances between the WaferGen Bio-systems, Inc. and its subsidiaries have been eliminated in consolidation.

Use of Estimates – Preparing condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Actual results and outcomes could differ from these estimates and assumptions.

Foreign Currencies – Assets and liabilities of non-U.S. subsidiaries for which the local currency is the functional currency are translated into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are translated at the average rates of exchange prevailing during each reporting period. Translation adjustments resulting from this process are charged or credited to other comprehensive income (loss). Foreign exchange gains and losses for assets and liabilities of the Company’s non-U.S. subsidiaries for which the functional currency is the U.S. dollar are recorded in miscellaneous income (expense) in the Company’s condensed consolidated statements of operations.

Accounts Receivable  An allowance for doubtful accounts will be recorded based on a combination of historical experience, aging analysis, and information on specific accounts. Account balances will be written off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Inventory – Inventory is recorded at the lower of cost (first-in, first-out) or market value. Additionally, the Company evaluates its inventory in terms of excess and obsolete exposures and records provisions as needed.

Goodwill and Long-lived Intangible AssetsGoodwill is tested for impairment on an annual basis in the fourth quarter and between annual tests if events occur or circumstances indicate that the carrying amount of goodwill may not be recoverable. Impairment losses, if any, are recorded in the statement of operations as “Impairment of goodwill.”

Long-lived intangibles are carried at cost less accumulated amortization and are subject to review for impairment when events or circumstances indicate that the carrying value may not be recoverable. Amortization is recognized over the estimated useful life of the respective asset on a straight-line basis except for customer lists, which are amortized in proportion to the present value of projected cash flows within their estimated useful lives, since this methodology more closely reflects the pattern in which economic benefits are derived.

Revenue Recognition – The Company recognizes revenue when (i) delivery of product has occurred or services have been rendered, (ii) there is persuasive evidence of a sale arrangement, (iii) selling prices are fixed or determinable, and (iv) collectability from the customers (individual customers and distributors) is reasonably assured. Revenue consists primarily of revenue generated from the sale of the Company’s products. Revenue is recorded when the risk and rewards of ownership are transferred to the Company’s customers (individual customers and distributors). This

 
5

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



generally occurs when the Company’s products are shipped from its facility as title has passed. Revenue is recorded net of estimated cash discounts. The Company estimates and accrues an allowance for sales returns at the time the product is sold. To date, sales returns have not been material.

Revenue from multi-deliverable arrangements is recognized for each element on delivery of product or completion of service. A typical multi-deliverable arrangement would be the shipment of capital equipment to a customer, followed by the delivery of services or of expendable equipment, provided such delivery is both probable and substantially within the Company’s control. Revenue for each deliverable is allocated based on full list selling prices, although if none of the deliverables is disproportionately discounted relative to the overall discount, this allocation is approximated by using the actual selling price of each deliverable to the customer. The actual cost of revenue for each deliverable is recognized when the revenue for that deliverable is recognized.

Governmental Subsidies – Incentives received from governments in the form of grants are recorded as a reduction in expense in accordance with their purpose. Grants awarded for the purpose of matching specified expenditures are not recognized until a definitive agreement has been signed by both parties; thereafter income is recognized to the extent that the related expenses have been incurred. The Company recognized governmental subsidies of $108,025 and $69,494 in the three months ended June 30, 2014 and 2013, respectively, and $172,540 and $149,590 in the six months ended June 30, 2014 and 2013, respectively, which were offset against operating expenses in the statement of operations.

Stock-Based Compensation – The Company measures the fair value of all stock-based awards to employees, including stock options, on the grant date and records the fair value of these awards, net of estimated forfeitures, to compensation expense over the service period. The fair value of awards to consultants is measured on the dates on which performance of services is completed, with interim valuations recorded at balance sheet dates while performance is in progress. The fair value of options is estimated using the Black-Scholes valuation model, and of restricted stock is based on the Company’s closing share price on the measurement date.

Change in Fair Value of Derivatives – The Company recognizes (or recognized until the time of their settlement) its warrants with certain cash settlement provisions or with certain anti-dilution protection, the redemption option of the Series A convertible preference shares of its Malaysian subsidiary, and the conversion element of its convertible promissory notes and of the Series B convertible preference shares of its Malaysian subsidiary as derivative liabilities. Such liabilities are valued when the financial instruments are initially issued or the derivative first requires recognition and are also revalued at each reporting date, with the change in their respective fair values being recorded as a gain or loss on revaluation within other income and expenses in the statement of operations. The Company determines the fair value of those warrants for which no anti-dilution adjustment is projected prior to the expiration date using the Black-Scholes valuation model, and all other derivative liabilities using a Monte Carlo Simulation approach, with key input variables provided by management.

Warranty Reserve – The Company’s standard warranty agreement is one year from shipment of certain products. The Company accrues for anticipated warranty costs upon shipment of these products. The Company’s warranty reserve is based on management’s judgment regarding anticipated rates of warranty claims and associated repair costs, and is updated quarterly.

Net Income (Loss) Per Share – Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding plus common share equivalents from conversion of dilutive stock options, warrants, and restricted stock using the treasury method, and convertible securities using the as-converted method, except when antidilutive. In the event of a net loss, the effects of all potentially dilutive shares are excluded from the diluted net loss per share calculation as their inclusion would be antidilutive.

Recent Accounting Pronouncements

In April 2014, the FASB issued ASU 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” (“ASU 2014-08”). ASU 2014-08 clarifies the circumstances under which discontinued operations should be reported and increases the disclosure requirements. ASU 2014-08 is effective for annual periods beginning after December 15, 2014, and interim periods within those years, and will become effective for the Company on January 1, 2015. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

 
6

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 will replace most of the existing revenue recognition guidance within U.S. GAAP. The core principle of this guidance is that an entity should recognize revenue for the transfer of goods or services to customers in an amount that it expects to be entitled to receive for those goods or services. In doing so, companies will be required to make certain judgments and estimates, including identifying contract performance obligations, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price among separate performance obligations. Further, ASU 2014-09 will require companies to make additional disclosures. ASU 2014-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those years, and will become effective for the Company beginning on January 1, 2017, with early adoption not permitted. ASU 2014-09 allows for two methods of adoption, a full retrospective method or a modified retrospective approach with the cumulative effect recognized at the date of initial application. The Company is in the process of determining the method of adoption and its impact on the Company’s consolidated financial condition and results of operations.


NOTE 3.  Acquisitions

On January 6, 2014, the Company acquired the Apollo Business (see Note 1). Since that date the results of its operations have been included in the consolidated financial statements. As a result of the acquisition, the Company can now offer a wide spectrum of products for sample preparation for NGS to laboratories performing targeted sequencing. The Company expects to achieve significant synergies, especially in its sales and marketing efforts, since the SmartChip and Apollo products and services serve the same customer base.

The total purchase price for the Apollo Business is summarized as follows:

Cash
 
$
2,000,000
 
Promissory note (see Note 6)
   
1,100,000
 
Contingent earn-out payments
   
410,000
 
         
Total
 
$
3,510,000
 

The contingent consideration arrangement requires the Company to pay IntegenX a percentage of revenues, on a sliding scale up to 20%, should certain revenue targets be achieved in 2014, 2015 and 2016. We estimated the fair value of the contingent consideration using a probability-weighted discounted cash flow model based on key assumptions including annual revenues ranging from $4.0 million to $9.9 million and a discount rate of 14%. This is measured as a Level 3 fair value liability.
 
In connection with the Apollo Business acquisition, the Company allocated the total purchase consideration to the net assets and liabilities acquired, including identifiable intangible assets, based on their respective fair values at the acquisition date. The following table summarizes the allocation of the purchase price to the fair value of the respective assets and liabilities acquired:

Inventory
 
$
606,000
 
Property and equipment
   
118,000
 
Intangible assets:
       
Customer lists and trademarks
   
1,500,000
 
Purchased technology
   
360,000
 
Goodwill (1)
   
990,000
 
Total assets
   
3,574,000
 
         
Liabilities – accrued vacation
   
(64,000
)
         
Total purchase price
 
$
3,510,000
 
__________

(1)
Goodwill, which represents the excess of the purchase price over the fair value of tangible and identified intangible assets acquired, is attributable primarily to expected synergies and the assembled workforce. All of the goodwill is expected to be deductible for income tax purposes except to the extent that it arose due to an over-estimate of contingent earn-out payments.


 
7

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



In addition, the Company incurred and expensed costs directly related to this acquisition totaling approximately $140,000, of which nil and $95,000 was incurred in the three and six months ended June 30, 2014, respectively, and are included in general and administrative expenses in the condensed consolidated statement of operations.

Selected amounts related to the Apollo Business included in the Company’s condensed consolidated statement of operations for the three and six months ended June 30, 2014, are as follows:

   
Period Ended June 30,
 
   
Three Months
   
Six Months
 
             
Revenue
  $ 582,785     $ 1,063,122  
                 
Net loss
  $ (568,000 )   $ (1,253,000 )

The unaudited pro forma information in the table below summarizes the combined results of operations of WaferGen Bio-systems, Inc. and subsidiaries with those of the Apollo Business as though these entities were combined as of January 1, 2013. The results of the Apollo Business for the three and six months ended June 30, 2013, are based on the actual historic quarterly allocations of the Abbreviated Financial Statements prepared for the year ended December 31, 2013, and for the three and six months ended June 30, 2014, are based on the Company’s results of operations, adjusted for estimated operating expenses in the five days prior to the acquisition. The pro forma financial information for all periods presented also includes the removal of direct acquisition-related costs, the additional charges for interest expense on acquisition-related borrowing, and the actual depreciation and amortization that would have been charged assuming the fair value adjustments to property and equipment and intangible assets had been applied as of January 1, 2013.

This unaudited pro forma information is summarized as follows:

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2014
   
2013
   
2014
   
2013
 
                         
Total revenue
  $ 1,733,908     $ 1,191,979     $ 3,139,421     $ 1,923,189  
                                 
Net loss
  $ (2,095,338 )   $ (3,442,957 )   $ (4,549,713 )   $ (7,663,415 )
                                 
Net loss per share - basic and diluted
  $ (2.27 )   $ (146.46 )   $ (4.96 )   $ (252.03 )

The pro forma financial information as presented above is for informational purposes only and is not indicative of the consolidated results of operations of future periods or the results of operations that would have been achieved had the acquisition had taken place on January 1, 2013.


NOTE 4.  Inventories

Inventories, net of provisions for potentially excess, obsolete or impaired goods, consisted of the following at June 30, 2014, and December 31, 2013:

   
June 30, 2014
   
December 31, 2013
 
             
Raw materials
  $ 77,256     $ 125,068  
                 
Work in process
    68,391       46,974  
                 
Finished goods
    694,161       120,608  
                 
Inventories
  $ 839,808     $ 292,650  



 
8

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



NOTE 5.  Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill in the six months ended June 30, 2014, were as follows:

Balance at January 1, 2014
 
$
 
         
Additions (see Note 3)
   
990,000
 
         
Balance at June 30, 2014
 
$
990,000
 

Other intangible assets as of June 30, 2014, consist of:

   
Gross
   
Net
   
Intangible
 
   
Carrying
   
Accumulated
   
Assets
 
   
Amount
   
Amortization
       
                         
Purchased technology
 
$
360,000
   
$
50,000
   
$
310,000
 
Customer lists and trademarks
   
1,500,000
     
199,000
     
1,301,000
 
                         
Total as of June 30, 2014
 
$
1,860,000
   
$
249,000
   
$
1,611,000
 

The estimated future amortization expenses by fiscal year are as follows:

Year ending December 31,
       
2014 (six months remaining)
 
$
248,900
 
2015
   
449,900
 
2016
   
421,000
 
2017
   
313,900
 
2018
   
148,500
 
Thereafter
   
28,800
 
         
Total amortization
 
$
1,611,000
 

Intangible asset amortization expense was $124,500 and nil for the three months ended June 30, 2014 and 2013, respectively, and $249,000 and nil for the six months ended June 30, 2014 and 2013, respectively.


NOTE 6.  Long Term Obligations

On May 27, 2011, the Company sold convertible promissory notes (“CPNs”) in the aggregate principal amount of $15,275,000, convertible into an aggregate of approximately 2,679,824 shares of Series A-2 Convertible Preferred Stock (see Note 8) at a price of $5.70 per share, with each 99.39 shares being convertible into one share of common stock. The CPNs were sold along with Series A-1 Convertible Preferred Stock and warrants for aggregate gross proceeds of $30,550,000, which after deducting issuance costs of $2,524,963 left net proceeds of $28,025,037. Interest on the CPNs accrued at a rate of 5% per annum, and could either be paid on the last day of each fiscal quarter, or added to the principal amount of the notes, at the Company’s option.

The debt discount related to the debt element of the convertible promissory notes of $14,442,497 was, prior to their exchange for equity securities on August 27, 2013 (the “2013 Exchange”), being amortized as non-cash interest expense using the effective yield method over the 3.5 year contractual term of the CPNs. $832,502 in issuance costs allocated to the CPNs was recorded as a deferred financing cost, which was also being amortized as a non-cash interest expense using the effective yield method over their 3.5 year contractual term.

The Company valued the derivative liability for the conversion element of the CPNs using a Monte Carlo Simulation approach, using assumptions provided by management reflecting conditions at the valuation dates.

The fair value of this derivative liability had diminished to nil by the time of the 2013 Exchange. The fair value of this derivative liability at June 30, 2013 and December 31, 2012, was estimated to be $439 and $274,928, respectively, using a closing stock price of $39.76 and $29.82, respectively, and based on the following assumptions:

 
9

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)




 
June 30, 2013
 
December 31, 2012
 
         
Risk-free interest rate
0.03%
 
0.13%
 
Remaining contractual term
1.41 Years
 
1.91 Years
 
Expected volatility
148.74%
 
126.91%
 
Dividend yield
0%
 
0%
 

The decrease in the fair value of this derivative liability of $274,489 during the six months ended June 30, 2013, was recorded as a revaluation gain (see Note 11).

On August 15, 2013, the Company issued WGBM notes with a face value of $6.6 million, maturing on August 15, 2020 (the “Malaysian Notes”), in consideration of WGBM’s cancellation of the Company’s obligations under a term loan owing to WGBM which, as of that date, had an outstanding loan balance of approximately $5.3 million. Under the terms of an agreement between the Company, WGBM and MTDC (see Notes 1 and 7), upon liquidation of WGBM (which occurred on November 26, 2013), the Malaysian Notes were divided such that the Company received notes with an aggregate principal amount of $1.4 million and MTDC received notes with an aggregate principal amount of $5.2 million (the “MTDC Notes”).

The MTDC Notes were recorded using an effective interest rate of 17.39% and are summarized as follows at June 30, 2014 and December 31, 2013:

   
June 30, 2014
   
December 31, 2013
 
             
MTDC Notes Payable:
           
Face value
  $ 5,200,000     $ 5,200,000  
Debt discount, net of accumulated amortization of $176,859 and $27,258 at June 30, 2014 and December 31, 2013, respectively
    3,366,457       3,516,058  
                 
Notes payable, net of debt discount
  $ 1,833,543     $ 1,683,942  

At any time prior to their maturity date, the Company may issue to MTDC shares of the Company’s common stock with a value, based on the average closing price in the preceding 30 days, equal to the face value of the MTDC Notes. Based on an average closing price of $13.08 in the 30 days preceding June 30, 2014, the MTDC Notes could have been settled by issuing 397,554 shares of the Company’s common stock.

As part of the consideration for the Apollo Business (see Notes 1 and 3), the Company issued a $1.25 million secured promissory note to IntegenX (the “IntegenX Note”), due on January 6, 2017 (the “Maturity Date”). The IntegenX Note earns simple interest at 8% per annum over its three year term, payable on the Maturity Date. It may be repaid early without premium or penalty at the Company’s option at any time and it must be repaid within 45 days of the closing of an equity offering yielding the Company net cash proceeds of at least $15,000,000.

The IntegenX Note was recorded using an effective interest rate of 11.60% and is summarized as follows at June 30, 2014 and January 6, 2014:

   
June 30, 2014
   
January 6, 2014
 
             
IntegenX Notes Payable:
           
Face value
  $ 1,250,000     $ 1,250,000  
Interest added to principal
    48,611        
Stated value
    1,298,611       1,250,000  
Debt discount, net of accumulated amortization of $14,270 and nil at June 30 and January 6, 2014, respectively
    135,730       150,000  
                 
Notes payable, net of debt discount
  $ 1,162,881     $ 1,100,000  



 
10

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



NOTE 7.  Convertible Preference Shares of Former Subsidiary

Prior to its dissolution in November 2013, in 2008, the Company’s former Malaysian subsidiary, WGBM, issued Series A Convertible Preference Shares (“CPS”) to MTDC (see Notes 1 and 6), a venture capital and development firm in Malaysia, in a private placement under a Share Subscription and Shareholders’ Agreement dated May 8, 2008, at the U.S. dollar equivalent of $2.25 per share. In 2009 and 2010, WGBM issued Series B CPS to Expedient Equity Ventures Sdn. Bhd. (“EEV”) and Prima Mahawangsa Sdn. Bhd. (“PMSB”), both venture capital and development firms in Malaysia, in a private placement under a Share Subscription Agreement dated April 3, 2009, (“Series B SSA”) at the U.S. dollar equivalent of $2.25 per share. In 2009, WGBM issued Series B CPS to Kumpulan Modal Perdana Sdn. Bhd. (“KMP”), a venture capital and development firm in Malaysia, in a private placement under a Share Subscription Agreement dated July 1, 2009, at the U.S. dollar equivalent of $2.25 per share.

In 2010, both EEV and KMP exercised their option to sell to the Company their holdings of 222,222 and 188,057 Series B CPS, respectively, in exchange for shares of the Company’s common stock.

In October 2013 the Company purchased PMSB’s 444,444 Series B CPS for $70,000.

These transactions, along with the issuance of Series C CPS in 2011 (see below), were summarized as follows immediately prior to the liquidation of WGBM on November 26, 2013:

Class
 
Number
 
Initial
 
Issuance
 
Gross
 
Issuance
 
Exchange
 
Net Cash
 
Date if
 
CPS
 
of CPS
 
of CPS
 
Investor
 
Date
 
Proceeds
 
(Costs)
 
Gain (loss)
 
Proceeds
 
Exchanged
 
Outstanding
 
                                               
Series A
 
444,444
 
MTDC
 
07/18/2008
 
$
1,000,000
 
$
(30,000
)
$
 
$
970,000
 
 
444,444
 
Series A
 
444,444
 
MTDC
 
11/27/2008
   
1,000,000
   
(30,000
)
 
   
970,000
 
 
444,444
 
Series B
 
111,111
 
EEV
 
06/08/2009
   
250,000
   
(19,393
)
 
(18,029
)
 
212,578
 
08/17/2010
 
 
Series B
 
111,111
 
EEV
 
03/09/2010
   
250,000
   
(8,929
)
 
(3,005
)
 
238,066
 
08/17/2010
 
 
Series B
 
222,222
 
PMSB
 
09/23/2009
   
500,000
   
(7,500
)
 
   
492,500
 
10/11/2013
 
 
Series B
 
222,222
 
PMSB
 
05/13/2010
   
500,000
   
(5,000
)
 
   
495,000
 
10/11/2013
 
 
Series B
 
188,057
 
KMP
 
09/18/2009
   
423,128
   
(11,319
)
 
   
411,809
 
09/29/2010
 
 
                                               
Subtotal
 
1,743,611
           
3,923,128
   
(112,141
)
 
(21,034
)
 
3,789,953
     
888,888
 
                                               
Series C
 
3,233,734
 
MTDC
 
03/10/2011
   
5,000,000
   
(6,272
)
 
58,575
   
5,052,303
 
 
3,233,734
 
                                               
   
4,977,345
         
$
8,923,128
 
$
(118,413
)
$
37,541
 
$
8,842,256
     
4,122,622
 

The holders of Series B CPS had the right to cause the Company to exchange their CPS for common stock of the Company at an exchange rate of US$2,236.30 per share of common stock, provided that if during the 10-day trading period immediately prior to the holder’s exercise notice the average closing price of the Company’s common stock was less than US$2,630.90, then the holder could exchange CPS at an exchange rate equal to 85% of such 10-day average closing price. Since this afforded the holders the right to receive a variable number of shares of the Company’s common stock, this feature was not indexed to the Company’s equity and was therefore accounted for as a derivative liability, with the estimated fair value being calculated at each reporting date using a Monte Carlo Simulation approach, using key input variables provided by management, with changes in fair value recorded as gains or losses on revaluation in non-operating income (expense).

Series B CPS derivative liability fair values at June 30, 2013 and December 31, 2012, were estimated to be $1,213,727 and $1,210,909, respectively, using a closing stock price of $39.76 and $29.82, respectively, and based on the following assumptions:

 
June 30, 2013
 
December 31, 2012
 
         
Risk-free interest rate
0.11%
 
0.16%
 
Expected remaining term
0.61 Years
 
1.00 Years
 
Expected volatility
135.80%
 
125.53%
 
Dividend yield
0%
 
0%
 

The increase in the fair value of this derivative liability of $2,818 during the six months ended June 30, 2013, was recorded as a revaluation loss (see Note 11).


 
11

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



The holders of Series A CPS had the right to redeem their shares for cash (or, at the Company’s option, shares of Company common stock at an Applicable Stock Price (“ASP”), calculated as 85% of the average closing price of that stock during the 10-day trading period immediately prior to MTDC’s exercise notice) in the amount originally invested in USD plus a premium of 8%, compounded annually. In addition, the ASP was subject to a ceiling of $1,540.55 and a floor of $99.39. Since this afforded the holders the right to receive a variable number of shares of the Company’s common stock, this feature caused the Series A CPS to not be indexed to the Company’s equity. As a result, the Company recognized this right as an embedded derivative requiring bifurcation and the host instrument (the Series A CPS absent this option) as part of temporary equity.

The Series A CPS derivative liability fair values at June 30, 2013 and December 31, 2012, were estimated to be $770,641 and $619,652, respectively, using a closing stock price of $39.76 and $29.82, respectively, and based on the following assumptions:

 
June 30, 2013
 
December 31, 2012
 
         
Risk-free interest rate
0.02% - 0.08%
 
0.11% - 0.15%
 
Expected remaining term
0.11 - 0.41 Years
 
0.55 - 0.90 Years
 
Expected volatility
111.30 - 123.77%
 
123.55 - 127.94%
 
Dividend yield
0%
 
0%
 

The increase in the fair value of this derivative liability of $150,989 during the six months ended June 30, 2013, was recorded as a revaluation loss (see Note 11).

On March 10, 2011, WGBM received $5,000,000, less issuance costs totaling $6,272, in exchange for the issuance of 3,233,734 Series C convertible preference shares (“CPS”) to MTDC, in a private placement at the U.S. dollar equivalent of $1.5462 per share, representing the first subscription under a Share Subscription Agreement dated December 14, 2010, (“Series C SSA”) to sell 3,233,734 Series C CPS at an initial closing and, should MTDC so elect within 36 months of the initial closing, to sell 1,077,911 shares of Series C CPS at a subsequent closing at the U.S. dollar equivalent of US$2.3193 per share. MTDC could also elect to convert their Series C CPS into ordinary shares of the subsidiary, WGBM, at any time, at a conversion rate of one ordinary share per 100 CPS. Each 993.9 Series C CPS issued at the initial closing was convertible into one share of the Company on April 3, 2014, and each 993.9 Series C CPS issued at the subsequent closing was convertible into one share of the Company on the anniversary of that closing, but the Series C was convertible at any earlier date following each closing at MTDC’s option.

The net sum of $4,993,728 received on issuance of Series C CPS was recorded in stockholders’ equity; this sum was considered in the determination of the gain on liquidation of subsidiary on November 26, 2013. WGBM was authorized to issue 200,000,000 preference shares with a par value of RM0.01. Due to the liquidation of WGBM, no shares remained authorized, issued or outstanding as of December 31, 2013.


NOTE 8.  Preferred Stock

The Company has 10,000,000 shares of preferred stock authorized. Effective August 27, 2013, the Company designated 3,663 shares as Series 1 Convertible Preferred Stock. The Series 1 Convertible Preferred Stock has no voting rights, and holders are entitled to a liquidation preference equal to $0.001 per share. Each share of Series 1 Convertible Preferred Stock is convertible into 2,515.3436 shares of common stock, subject to an ownership cap whereby conversion may not occur to the extent the holder would own more than 9.98% of the common stock following conversion.

On August 27, 2013, the Company issued 2,987.0168 shares of Series 1 Convertible Preferred Stock in exchange for CPNs (see Note 6) and Series A-1 Convertible Preferred Stock (see below) and sold 646.0351 shares of Series 1 Convertible Preferred Stock in a private placement (the “2013 Private Placement”). Of the 3,633.0519 shares of Series 1 Convertible Preferred Stock, 762.7632 have been converted into 191,861 shares of common stock and 2,870.2887 remain outstanding as of June 30, 2014.

Effective May 26, 2011, the Company designated 4,500,000 shares as Series A-1 Convertible Preferred Stock and 4,500,000 shares as Series A-2 Convertible Preferred Stock (together, the “Series A Preferred Stock”). Each 99.39 shares of Series A Preferred Stock was convertible into one share of common stock, subject to an ownership cap, and entitled the holder to receive dividends, as, when and if declared by the Company’s Board of Directors, at an annual rate of 5% of the stated value per share of the respective series. Such dividends accrued, compounding quarterly, and

 
12

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



accumulated on each share of Series A Preferred Stock from the date of issuance, whether or not declared, until November 27, 2014, when the right to further dividends would cease. The Series A Preferred Stock had no voting rights, and in the event of liquidation ranked senior to common stock.

Effective May 27, 2011, the Company sold an aggregate of 2,937,500 shares of Series A-1 Convertible Preferred Stock with a stated value of $5.20 per share. $209,268 and $415,952 was accrued with respect to undeclared dividends in the three and six months ended June 30, 2013, respectively. All of the Series A-1 Convertible Preferred Stock was exchanged for common stock and Series 1 Convertible Preferred Stock in the 2013 Exchange, following which the Company retired all of the Series A Preferred Stock, none of which remains issued and outstanding and none will be issued in the future.


NOTE 9.  Stock Awards

The Company has awards outstanding under three plans - the 2003 Incentive Stock Plan (the “2003 Plan”), the 2007 Stock Option Plan (the “2007 Plan”) and the 2008 Stock Incentive Plan (the “2008 Plan”) (collectively, the “Plans”). Under the 2003 Plan and 2007 Plan, incentive stock options, nonqualified stock options, restricted stock and restricted stock units could be granted. Awards vested over varying periods, as specified by the Company’s Board of Directors for each grant, and are exercisable for a maximum period of ten years after date of grant. Both of these plans have been frozen, resulting in no further shares being available for grant.

The Company presently issues awards under the 2008 Plan, initially adopted by the Company’s stockholders on June 5, 2008, and subsequently amended to authorize the issuance of additional shares of the Company’s common stock. This includes an amendment adopted by the Company’s stockholders on May 29, 2014, which increased the total number of shares authorized for issuance from 14,589 to 314,589. The purpose of the 2008 Plan is to provide an incentive to retain the employment of directors, officers, consultants, advisors and employees of the Company, to attract new personnel whose training, experience and ability are considered valuable, to encourage the sense of proprietorship, and to stimulate the active interest of such persons in the Company’s development and financial success. Under the 2008 Plan, the Company is authorized to issue incentive stock options, non-qualified stock options, restricted stock and restricted stock units. Awards that expire or are canceled generally become available for issuance again under the 2008 Plan. The number of shares of the Company’s common stock available under the 2008 Plan will be subject to adjustment in the event of a stock split, stock dividend or other extraordinary dividend, or other similar change in the Company’s common stock or capital structure. Awards may vest over varying periods, as specified by the Company’s Board of Directors for each grant, and have a maximum term of seven years from the grant date. The 2008 Plan is administered by the Company’s Board of Directors.

The Company has issued both options and restricted stock (including restricted stock units) under these Plans. Restricted stock grants afford the recipient the opportunity to receive shares of common stock, subject to certain terms, whereas options give them the right to purchase common stock at a set price. Both the Company’s options and restricted stock issued to employees generally have vesting restrictions that are eliminated over a four-year period, although vesting may be over a shorter period, or may occur on the grant date, depending on the terms of each individual award.

A summary of stock option and restricted stock transactions in the six months ended June 30, 2014, is as follows:

       
Stock Options
 
Restricted Stock
 
           
Weighted
     
Weighted
 
   
Shares
 
Number of
 
Average
 
Number of
 
Average
 
   
Available
 
Options
 
Exercise
 
Shares
 
Grant Date
 
   
For Grant
 
Outstanding
 
Price
 
Outstanding
 
Fair Value
 
                                 
Balance at January 1, 2014
   
2,779
   
11,353
 
$
353.92
   
 
$
 
2008 Plan Amendment
   
300,000
   
 
$
   
 
$
 
Granted
   
(85,970
)
 
79,558
 
$
14.00
   
6,412
 
$
14.00
 
Forfeited
   
241
   
(241
)
$
124.78
   
––
 
$
––
 
Canceled
   
1,696
   
(1,729
)
$
215.62
   
––
 
$
––
 
                                 
Balance at June 30, 2014
   
218,746
   
88,941
 
$
53.12
   
6,412
 
$
14.00
 

No options were exercised during the six months ended June 30, 2014 or 2013. The aggregate intrinsic value of options outstanding and exercisable at June 30, 2014, was nil, based on our common stock closing price of $12.50. Aggregate

 
13

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



intrinsic value is the total pretax amount (i.e., the difference between the Company’s stock price and the exercise price) that would have been received by the option holders had all their in-the-money options been exercised.

The weighted average grant date fair value of options awarded in the six months ended June 30, 2014 and 2013, was $9.86 and $37.24, respectively. Fair values were estimated using the following assumptions:

 
Six Months Ended June 30,
 
 
2014
 
2013
 
         
Risk-free interest rate
1.43%
 
0.71%
 
Expected term
4.75 Years
 
4.75 Years
 
Expected volatility
93.89%
 
108.14%
 
Dividend yield
0%
 
0%
 

The amounts expensed for stock-based compensation totaled $687,660 and $77,983 for the three months ended June 30, 2014 and 2013, respectively, and $759,534 and $182,785 for the six months ended June 30, 2014 and 2013, respectively.

At June 30, 2014, the total stock-based compensation cost not yet recognized, net of estimated forfeitures, was $356,902. This cost is expected to be recognized over an estimated weighted average amortization period of 0.82 years. No amounts related to stock-based compensation costs have been capitalized. The tax benefit and the resulting effect on cash flows from operating and financing activities related to stock-based compensation costs were not recognized as the Company currently provides a full valuation allowance for all of its deferred taxes.


NOTE 10.  Warrants

A summary of outstanding common stock warrants as of June 30, 2014, is as follows:

Securities Into Which
 
Total Warrants
 
Warrants Recorded
 
Exercise
 
Expiration
Warrants are Convertible
 
Outstanding
 
as Liabilities
 
Price
 
Date
                 
Common stock
 
612,838
 
110,527
 
$26.00
 
August and September 2018
Common stock
 
28,242
 
28,242
 
$40.40
 
August 2014
Common stock
 
55,219
 
55,219
 
$42.20
 
December 2014 and January 2015
Common stock
 
154
 
 
$775.24
 
August 2014
Common stock
 
102
 
 
$834.88
 
December 2014
Common stock
 
96
 
 
$1,459.05
 
December 2015
Common stock
 
205
 
 
$1,490.85
 
July 2015
Common stock
 
3,019
 
 
$1,540.55
 
July 2015
Common stock
 
201
 
 
$2,981.70
 
December 2014 and November 2015
                 
Total
 
700,076
 
193,988
       

In addition, there are 25.88 unit warrants outstanding which expire in August and September 2018, 0.35 of which are recorded as liabilities, each entitling the holder to purchase, for $50,000, 2,500 shares of common stock and 1,250 warrants to purchase one share of common stock at an exercise price of $26.00, expiring in August and September 2018.

The warrants expiring in August 2014 were originally issued in August 2009 with an exercise price of $1,987.80 and entitled the holders thereof to purchase an aggregate of 634 shares. As a result of anti-dilution adjustments with respect to such warrants pursuant to their terms, such warrants, as of May 27, 2011, had an exercise price of $775.24 and entitled the holders thereof to purchase an aggregate of 1,626 shares. In connection with the May 2011 Private Placement, members of management with warrants to purchase a total of 154 shares (after giving effect to prior anti-dilution adjustments) waived their right to further anti-dilution adjustments. As a result of anti-dilution adjustments with respect to the remaining 1,472 warrants pursuant to their terms, such warrants, as of June 30, 2014, had an exercise price of $40.40 and entitled the holders thereof to purchase an aggregate of 28,242 shares.

The warrants expiring in December 2014 and January 2015 were originally issued in December 2009 and January 2010 with an exercise price of $2,484.75 and entitled the holders thereof to purchase an aggregate of 972 shares. As a result

 
14

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



of anti-dilution adjustments with respect to such warrants pursuant to their terms, such warrants, as of May 27, 2011, had an exercise price of $834.88 and entitled the holders thereof to purchase an aggregate of 2,893 shares. In connection with the May 2011 Private Placement, members of management with warrants to purchase a total of 102 shares (after giving effect to prior anti-dilution adjustments) waived their right to further anti-dilution adjustments. As a result of anti-dilution adjustments with respect to the remaining 2,791 warrants pursuant to their terms, such warrants, as of June 30, 2014, had an exercise price of $42.20 and entitled the holders thereof to purchase an aggregate of 55,219 shares.

The Company records warrants and unit warrants with certain anti-dilution protection or certain cash settlement provisions as liabilities, with the estimated fair value of those warrants for which no anti-dilution adjustment is projected prior to the expiration date being calculated using the Black-Scholes valuation model, with all others being calculated using a Monte Carlo Simulation approach, using key input variables provided by management, at each reporting date. Changes in fair value are recorded as gains or losses on revaluation in non-operating income (expense).

The warrants expiring in August and September 2018 comprise 236,900 warrants issued in the 2013 Exchange and 341,713 and 34,225 issued in the initial and final closing, respectively, of the 2013 Private Placement. As the result of a provision contained in these warrants and the unit warrants that were issued in August and September 2013 that would have required cash settlement in certain rare circumstances, these securities were required to be classified as liabilities on the Company’s Consolidated Balance Sheet. In an effort to reduce the amount of such liabilities, which totaled approximately $8.7 million as of December 31, 2013, in March 2014 the Company began requesting holders of these warrants and unit warrants to consent to amendments to their terms to enable the Company to reclassify them as equity.

On March 31, 2014, the Company amended the terms of 412,933 warrants and 22.54 unit warrants such that the liability was settled, having received consent from their holders. The fair value of the securities settled and reclassified as equity on March 31, 2014, was estimated to be $6,109,179. On June 30, 2014, the Company amended the terms of a further 89,378 warrants and 2.99 unit warrants such that the liability was settled, having received consent from their holders after March 31, 2014. The fair value of the securities settled and reclassified as equity on June 30, 2014, was estimated to be $711,960, based on assumptions described below.

The total fair values of those warrants and unit warrants accounted for as liabilities as of June 30, 2014 and 2013, was estimated to be $952,172 and $701,857, respectively, using a closing stock price of $12.50 and $39.76, respectively, and based on the following assumptions:

 
June 30, 2014
 
June 30, 2013
 
         
Risk-free interest rate
0.03% - 1.03%
 
0.13% - 0.19%
 
Expected remaining term
0.15 - 3.40 Years
 
0.77 - 1.19 Years
 
Expected volatility
103.32% - 123.85%
 
130.24% - 131.31%
 
Dividend yield
0%
 
0%
 

The aggregate fair value of such warrants and unit warrants at December 31, 2013 and 2012, was estimated to be $9,147,507 and $102,695, respectively. During the six months ended June 30, 2014, to the extent that it did not arise from settlements, a decrease in the fair value of the warrant derivative liability of $1,374,196 was recorded as a revaluation gain and during the six months ended June 30, 2013, an increase in the fair value of the warrant derivative liability of $599,162 was recorded as a revaluation loss (see Note 11).


NOTE 11.  Fair Value of Financial Instruments

Fair value measurements are determined under a three-level hierarchy for fair value measurements that prioritizes the inputs to valuation techniques used to measure fair value, distinguishing between market participant assumptions developed based on market data obtained from sources independent of the reporting entity (“observable inputs”) and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (“unobservable inputs”).

Fair value is the price that would be received to sell an asset or would be paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company primarily uses prices and other relevant information generated by market transactions involving identical or comparable assets (“market approach”). The Company also considers the impact of a significant decrease in volume

 
15

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



and level of activity for an asset or liability when compared with normal activity to identify transactions that are not orderly.

The highest priority is given to unadjusted quoted prices in active markets for identical assets (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Securities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The three hierarchy levels are defined as follows:

Level 1 – Quoted prices in active markets that are unadjusted and accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2 – Quoted prices for identical assets and liabilities in markets that are not active, quoted prices for similar assets and liabilities in active markets or financial instruments for which significant inputs are observable, either directly or indirectly;

Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

The following tables present the Company’s liabilities that are measured at fair value on a recurring basis at June 30, 2014 and December 31, 2013:

   
Level 1
   
Level 2
   
Level 3
   
Total
 
June 30, 2014
                       
Financial Liabilities:
                       
Warrant derivative liabilities
  $     $     $ 952,172     $ 952,172  
                                 
Total liabilities
  $     $     $ 952,172     $ 952,172  

   
Level 1
   
Level 2
   
Level 3
   
Total
 
December 31, 2013
                       
Financial Liabilities:
                       
Warrant derivative liabilities
  $     $     $ 9,147,507     $ 9,147,507  
                                 
Total liabilities
  $     $     $ 9,147,507     $ 9,147,507  


The following tables present a reconciliation of all liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months ended June 30, 2014 and 2013:

         
Conversion
                   
         
Element of
   
Conversion
             
   
Warrant
   
Promissory
   
Element of
   
Series A CPS
       
   
Derivatives
   
Notes
   
Series B CPS
   
Derivatives
   
Total
 
                               
Balance at January 1, 2014
  $ 9,147,507     $     $     $     $ 9,147,507  
Issuances
                             
Revaluation gains included in other income and expenses
    (1,374,196 )                       (1,374,196 )
Settlements
    (6,821,139 )                       (6,821,139 )
Balance at June 30, 2014
  $ 952,172     $     $     $     $ 952,172  
                                         
Total gains included in other income and expenses attributable to liabilities still held as of June 30, 2014
  $ 776,495     $     $     $     $ 776,495  


 
16

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)




         
Conversion
                   
         
Element of
   
Conversion
             
   
Warrant
   
Promissory
   
Element of
   
Series A CPS
       
   
Derivatives
   
Notes
   
Series B CPS
   
Derivatives
   
Total
 
                               
Balance at January 1, 2013
  $ 102,695     $ 274,928     $ 1,210,909     $ 619,652     $ 2,208,184  
Issuances
                             
Revaluation (gains) losses included in other income and expenses
    599,162       (274,489 )     2,818       150,989       478,480  
Settlements
                             
Balance at June 30, 2013
  $ 701,857     $ 439     $ 1,213,727     $ 770,641     $ 2,686,664  
                                         
Total gains (losses) included in other income and expenses attributable to liabilities still held as of June 30, 2013
  $ (599,163 )   $ 274,489     $ (2,818 )   $ (150,989 )   $ (478,481 )

Assumptions used in evaluating the warrant derivative liabilities, the conversion element of the promissory notes, the conversion element of the Series B CPS and the Series A CPS derivative liabilities are discussed in Notes 10, 6, 7 and 7, respectively. The principal assumptions used, and their impact on valuations, are as follows:

Risk-Free Interest Rate.  This is the U.S. Treasury rate for the measurement date having a term equal to the weighted average expected remaining term of the instrument. An increase in the risk-free interest rate will increase the fair value and the associated derivative liability.

Expected Remaining Term.  This is the period of time over which the instrument is expected to remain outstanding and is based on management’s estimate, taking into consideration the remaining contractual life, historical experience and the possibility of liquidation. An increase in the expected remaining term will increase the fair value and the associated derivative liability.

Expected Volatility.  This is a measure of the amount by which the Company’s common stock price has fluctuated or is expected to fluctuate. The Company applies equal weighting to the Company’s own historic volatility and the historic volatility of a group of publicly traded companies over the retrospective period corresponding to the expected remaining term of the instrument on the measurement date. Since the 2013 Exchange, the Company has applied a reduced weighting to its own historic volatility during the period in which it was highly leveraged. The group of publicly traded companies is selected from the same industry or market index, with extra weighting attached to those companies most similar in terms of business activity, size and financial leverage. An increase in the expected volatility will increase the fair value and the associated derivative liability.

Dividend Yield.  The Company has not made any dividend payments and does not plan to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value and the associated derivative liability.


NOTE 12.  Net Loss Per Share

Basic and diluted net loss per share are shown on the statement of operations.

No adjustment has been made to the net loss for charges, gains, losses and accretion related to Series A, B and C CPS, MTDC Notes, Series A-1 Convertible Preferred Stock and CPNs, as the effect would be anti-dilutive due to the net loss.

The following outstanding stock options (on an as-converted into common stock basis) and shares issuable or contingently issuable upon conversion of restricted stock, Series 1 Convertible Preferred Stock, Series A, B and C CPS, MTDC Notes, Series A-1 Convertible Preferred Stock and CPNs were excluded from the computation of diluted net loss per share attributable to holders of common stock as they had antidilutive effects for the three and six months ended June 30, 2014 and 2013:

 
17

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)




   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2014
   
2013
   
2014
   
2013
 
                         
Common share equivalents issuable upon exercise of common stock options
    2,365       64       3,406       70  
                                 
Shares issuable upon vesting of restricted stock
    2,325             1,169        
                                 
Shares issuable upon conversion of Series 1 convertible preferred stock
    731,027             735,834        
                                 
Shares issuable upon conversion of Series A CPS
          29,065             29,065  
                                 
Shares issuable upon conversion of Series B CPS
          29,592             29,592  
                                 
Shares issuable upon conversion of Series C CPS
          3,254             3,254  
                                 
Shares issuable upon conversion of MTDC Notes
    397,554             397,554        
                                 
Shares issuable upon conversion of Series A-1 convertible preferred stock
          32,562             32,360  
                                 
Shares issuable upon conversion of  convertible promissory notes
          29,744             29,562  
                                 
Total common share equivalents excluded from denominator for diluted earnings per share computation
    1,133,271       124,281       1,137,963       123,903  


NOTE 13.  Concentrations

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and accounts receivable. The Company places its cash in commercial banks. Accounts in the United States are secured by the Federal Deposit Insurance Corporation. Accounts in Luxembourg are similarly guaranteed. The Company’s total deposits at commercial banks usually exceed the balances insured.

The Company generally requires no collateral from its customers. No provision was made for doubtful accounts at June 30, 2014, or December 31, 2013.

Customers accounting for more than 10% of total revenues during the three or six months ended June 30, 2014 or 2013, are tabulated as follows:

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2014
   
2013
   
2014
   
2013
 
                                                 
Customer A
  $ 241,234       14 %   $           $ 241,234       8 %   $        
Customer B
  $ 224,536       13 %   $           $ 225,466       7 %   $        
Customer C
  $ 202,278       12 %   $           $ 213,476       7 %   $        
Customer D
  $ 182,070       10 %   $           $ 278,908       9 %   $        
Customer E
  $ 125,000       7 %   $ 125,000       51 %   $ 250,000       8 %   $ 208,333       49 %
Customer F
  $           $ 77,519       31 %   $ 164,336       5 %   $ 161,242       38 %
Customer G
  $ 50,311       3 %   $ 26,870       11 %   $ 183,425       6 %   $ 26,870       6 %


NOTE 14.  Contingencies

From time to time the Company may be involved in claims arising in connection with its business. Based on information currently available, the Company believes that the amount, or range, of reasonably possible losses in connection with any pending actions against it, including the matter described below, in excess of established reserves,

 
18

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Notes to the Condensed Consolidated Financial Statements (Unaudited)



in the aggregate, not to be material to its consolidated financial condition or cash flows. However, losses may be material to the Company’s operating results for any particular future period, depending on the level of income or loss for such period.

Coalesce v. WaferGen.  On April 24, 2012, an action entitled Coalesce Corporation (“Coalesce”) v. WaferGen Bio-systems, Inc. was filed in the Alameda County Superior Court. Coalesce, a company that had been providing marketing services between 2006 and 2010, sued the Company for alleged non-payment of sums due, breach of contract, misrepresentation and unjust enrichment. On September 5, 2012, Coalesce filed an amended complaint, with additional claims, for compensatory damages in excess of $500,000 and other compensation. In August 2014, the plaintiff and Company agreed to an out-of-court settlement, with certain details to be finalized in a formal written agreement. The Company recorded an expense of $110,000 in the three months ended June 30, 2014, to increase the sum accrued to the amount of the out-of-court settlement. Related legal costs were expensed as incurred..




Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion highlights the principal factors that have affected our financial condition and results of operations as well as our liquidity and capital resources for the periods described.

The information contained in this Form 10-Q is intended to update the information contained in our annual report on Form 10-K for the year ended December 31, 2013 (the “Form 10-K”), and our quarterly report on Form 10-Q for the quarter ended March 31, 2014 (the “First Quarter Form 10-Q”), both as filed with the Securities and Exchange Commission, and presumes that readers have access to, and will have read, the “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” our consolidated financial statements and the notes thereto, and other information contained in the Form 10-K and the First Quarter Form 10-Q. The following discussion and analysis also should be read together with our condensed consolidated financial statements and the notes thereto included elsewhere in this Form 10-Q.

Forward-Looking Statements

Information included in this Form 10-Q may contain forward-looking statements. Except for the historical information contained in this discussion of the business and the discussion and analysis of financial condition and results of operations, the matters discussed herein are forward looking statements. These forward looking statements include but are not limited to our plans for sales growth and expectations of gross margin, expenses, new product introduction, integration and potential benefits of our recent business acquisition, and our liquidity and capital needs. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “estimate,” “believe,” “intend,” “contemplate,” “predict,” “project,” “potential” or “continue” or the negative of these words or other variations on these words or comparable terminology. In addition to the risks and uncertainties described in “Risk Factors” contained in the Form 10-K, these risks and uncertainties may include consumer trends, business cycles, scientific developments, changes in governmental policy and regulation, currency fluctuations, economic trends in the United States and inflation. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Our actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Company Overview and Background

Since beginning operations in 2003, we have been engaged in the development, manufacture and sales of systems for gene expression quantification, genotyping and stem-cell research for the life sciences and pharmaceutical drug discovery industries. Most recently, our R&D efforts have been concentrated on the commercialization of the SmartChip Target Enrichment System. Our products are aimed at researchers who perform genetic analysis and cell biology, primarily at pharmaceutical and biotech companies, academic and private research centers and diagnostics companies involved in biomarker research. We plan to provide new performance standards with significant savings of time and cost for professionals in the field of gene expression research and to facilitate biomarker discovery, toxicology and clinical research through the SmartChip products and services.

Our revenue is subject to fluctuations due to the timing of sales of high-value products and service projects, the impact of seasonal spending patterns, the timing and size of research projects our customers perform, changes in overall spending levels in the life science industry and other unpredictable factors that may affect customer ordering patterns. Any significant delays in the commercial launch or any lack or delay of commercial acceptance of new products, unfavorable sales trends in existing product lines, or impacts from the other factors mentioned above, could adversely affect our revenue growth or cause a sequential decline in quarterly revenue. Due to the possibility of fluctuations in our revenue and net income or loss, we believe that quarterly comparisons of our operating results are not a good indicator of future performance.

Since inception, we have incurred substantial operating losses. As of June 30, 2014, our accumulated deficit was $85,487,196. Losses have principally occurred as a result of the substantial resources required for the research, development and manufacturing start-up costs required to commercialize our initial products. We expect to continue to incur substantial costs for research and development activities for at least the next year as we expand and improve our core technology and its applications in the life science research market.



Acquisition of Assets from IntegenX Inc.

In January 2014, we entered into an Asset Purchase Agreement with IntegenX Inc. (“IntegenX”), pursuant to which we acquired substantially all of the assets of its product line used in connection with developing, manufacturing, marketing and selling instruments and reagents relating to library preparation for next generation sequencing, including the Apollo 324TM instrument and the PrepXTM reagents (the “Apollo Business”). The purchase price for the Apollo Business comprised (1) a cash payment of $2.0 million, (2) a $1.25 million secured promissory note (the “IntegenX Note”), (3) up to three earn-out payments payable, if at all, in 2015, 2016 and 2017, respectively (the “Earnout”), and (4) our assumption of certain liabilities, including obligations to perform under contracts and liabilities for certain accrued but unpaid vacation for certain employees.

The IntegenX Note accrues interest at 8.0% per year and is payable in a single payment of principal and accrued interest on January 6, 2017. However if, prior to the IntegenX Note’s maturity, we complete an equity offering yielding net cash proceeds of at least $15.0 million, we will be required to prepay the IntegenX Note within 45 days of the closing of the equity offering. To secure our obligations under the IntegenX Note, we granted IntegenX a security interest in the assets acquired from them.

The Earnout contemplates three earn-out payments based on gross revenues from certain products of the Apollo Business (“Covered Revenues”). In particular:

 
·
If, in 2014, Covered Revenues exceed $4 million but are less than $6 million, we will pay IntegenX an amount equal to 15% of the amount by which the 2014 Covered Revenues exceed $4 million. If, in 2014, Covered Revenues exceed $6 million, we will pay IntegenX an amount equal to the sum of (i) $300,000 plus (ii) 20% of the amount by which the 2014 Covered Revenues exceed $6 million.

 
·
If, in 2015, Covered Revenues exceed $4 million but are less than $6 million, we will pay IntegenX an amount equal to 10% of the amount by which the 2015 Covered Revenues exceed $4 million. If, in 2015, Covered Revenues exceed $6 million but are less than $10 million, we will pay IntegenX an amount equal to the sum of (i) $200,000 plus (ii) 15% of the amount by which the 2015 Covered Revenues exceed $6 million. If, in 2015, Covered Revenues exceed $10 million, we will pay IntegenX an amount equal to (i) $800,000 plus (ii) 20% of the amount by which the 2015 Covered Revenues exceed $10 million.

 
·
If, in 2016, Covered Revenues exceed $4 million but are less than $10 million, we will pay IntegenX an amount equal to 10% of the amount by which the 2016 Covered Revenues exceed $4 million. If, in 2016, Covered Revenues exceed $10 million but are less than $15 million, we will pay IntegenX an amount equal to the sum of (i) $600,000 plus (ii) 15% of the amount by which the 2016 Covered Revenues exceed $10 million. If, in 2016, Covered Revenues exceed $15 million, we will pay IntegenX an amount equal to (i) $1.35 million plus (ii) 20% of the amount by which the 2016 Covered Revenues exceed $15 million.

On June 30, 2014, we effected a reverse stock split of our common stock by a ratio of one-for-ten (the “2014 Reverse Split”). Every ten outstanding shares of common stock became one share of common stock. No fractional shares were issued in connection with the 2014 Reverse Split. Stockholders who were otherwise entitled to receive a fractional share of common stock received one whole share of common stock. The 2014 Reverse Split did not change the number of shares of common or preferred stock that we are authorized to issue, or the par value of our common or preferred stock.  Except as otherwise noted in this Quarterly Report on Form 10-Q, all share numbers are presented on a post-2014 Reverse Split basis.


Results of Operations

The following table presents selected items in the condensed consolidated statements of operations for the three and six months ended June 30, 2014 and 2013, respectively:

   
Three Months Ended June 30,
   
Six Months Ended June 30,
 
   
2014
   
2013
   
2014
   
2013
 
                         
Revenue:
                       
Product
  $ 1,608,908     $ 121,248     $ 2,889,421     $ 216,402  
License and royalty
    125,000       125,000       250,000       208,333  
                                 
Total revenue
    1,733,908       246,248       3,139,421       424,735  
                                 
Cost of product revenue
    758,408       76,780       1,364,981       142,368  
                                 
Gross profit
    975,500       169,468       1,774,440       282,367  
                                 
Operating expenses:
                               
Sales and marketing
    1,364,200       609,296       2,636,989       951,927  
Research and development
    1,472,886       1,263,267       2,839,883       2,665,347  
General and administrative
    1,289,508       564,770       2,101,043       1,225,418  
                                 
Total operating expenses
    4,126,594       2,437,333       7,577,915       4,842,692  
                                 
Operating loss
    (3,151,094 )     (2,267,865 )     (5,803,475 )     (4,560,325 )
                                 
Other income and (expenses):
                               
Interest income
    19       892       27       2,087  
Interest expense
    (109,155 )     (1,092,091 )     (212,482 )     (1,972,629 )
Gain (loss) on revaluation of derivative liabilities, net
    1,158,240       115,237       1,374,196       (478,480 )
Miscellaneous income (expense)
    (1,422 )     79,621       (4,193 )     67,343  
                                 
Total other income and (expenses)
    1,047,682       (896,341 )     1,157,548       (2,381,679 )
                                 
Net loss before provision for income taxes
    (2,103,412 )     (3,164,206 )     (4,645,927 )     (6,942,004 )
                                 
Provision for income taxes
          (1,051 )     3,100       2,661  
                                 
Net loss
  $ (2,103,412 )   $ (3,163,155 )   $ (4,649,027 )   $ (6,944,665 )


Product Revenue

The following table presents our product revenue for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
1,608,908
 
$
121,248
 
1,227%
   
$
2,889,421
 
$
216,402
 
1,235%

For the three months ended June 30, 2014, product revenue increased by $1,487,660, or 1,227%, as compared to the three months ended June 30, 2013. The increase is primarily due to additional sales of SmartChip Real-Time PCR Systems and SmartChip Target Enrichment Systems (launched in mid-2013) in the three months ended June 30, 2014, representing 46% of our product revenue. Sales from the newly-acquired Apollo Business accounted for 36% of our product revenue in the three months ended June 30, 2014, compared to none in the comparable 2013 period. There was also a significant increase in sales of our Real-Time PCR Chip panels, which represented 17% of revenue in the three months ended June 30, 2014.



For the six months ended June 30, 2014, product revenue increased by $2,673,019, or 1,235%, as compared to the six months ended June 30, 2013. The increase is primarily due to additional sales of SmartChip Real-Time PCR Systems and SmartChip Target Enrichment Systems (launched in mid-2013) in the six months ended June 30, 2014, representing 47% of our product revenue. Sales from the newly-acquired Apollo Business accounted for 37% of our product revenue in the six months ended June 30, 2014, compared to none in the comparable 2013 period. There was also a significant increase in sales of our Real-Time PCR Chip panels, which represented 16% of revenue in the six months ended June 30, 2014.

License and Royalty Revenue

The following table presents our license and royalty revenue for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
125,000
 
$
125,000
 
   
$
250,000
 
$
208,333
 
20%

For the three months ended June 30, 2014 and 2013, license and royalty revenue was unchanged at $125,000. For the six months ended June 30, 2014, license and royalty revenue increased by $41,667, or 20%, as compared to the six months ended June, 2013. The increase reflects revenue recognition for one additional month in the six months ended June 30, 2014. This revenue was generated by an agreement signed at the beginning of February 2013, expected to generate revenue of $500,000 annually for three years.

Cost of Product Revenue

The following table presents the cost of product revenue for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
758,408
 
$
76,780
 
888%
   
$
1,364,981
 
$
142,368
 
859%

Cost of product revenue includes the cost of products paid to third party vendors, raw materials, labor and overhead for products manufactured internally, and reserves for warranty and inventory obsolescence.

For the three months ended June 30, 2014, cost of product revenue increased by $681,628, or 888%, as compared to the three months ended June 30, 2013. For the six months ended June 30, 2014, cost of product revenue increased by $1,222,613, or 859%, as compared to the six months ended June 30, 2013. The increase in both the three- and six-month periods ended June 30, 2014, related primarily to the increase in product revenue, offset by improved margins, partly caused by reductions in the provision for excess inventory.

Sales and Marketing

The following table presents sales and marketing expenses for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
1,364,200
 
$
609,296
 
124%
   
$
2,636,989
 
$
951,927
 
177%

Sales and marketing expenses consist primarily of compensation costs of our sales and marketing team, commissions and the costs associated with various marketing programs.

For the three months ended June 30, 2014, sales and marketing expenses increased by $754,904, or 124%, as compared to the three months ended June 30, 2013. The increase resulted primarily from increases in headcount, largely due to our hiring employees from the Apollo Business, an additional expense recorded for an out-of-court settlement, increased commissions due to increased revenue, amortization expense and the scale-up of marketing activities.

For the six months ended June 30, 2014, sales and marketing expenses increased by $1,685,062, or 177%, as compared to the six months ended June 30, 2013. The increase resulted primarily from increases in headcount, largely due to our hiring employees from the Apollo Business, an additional expense recorded for an out-of-court settlement, increased commissions due to increased revenue, amortization expense and the scale-up of marketing activities, including one major trade show.


We expect sales and marketing expenses for the remainder of 2014 to remain at a similar level to that of the first two quarters.

Research and Development

The following table presents research and development expense for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
1,472,886
 
$
1,263,267
 
17%
   
$
2,839,883
 
$
2,665,347
 
7%

Research and development expenses consist primarily of salaries and other personnel-related expenses, laboratory supplies and other expenses related to the design, development, testing and enhancement of our products. Research and development expenses are expensed as they are incurred.

For the three months ended June 30, 2014, research and development expenses increased by $209,619, or 17%, as compared to the three months ended June 30, 2013. For the six months ended June 30, 2014, research and development expenses increased $174,536, or 7%, as compared to the six months ended June 30, 2013. The increase in both periods resulted primarily from increases in headcount, most notably due to our hiring employees from the Apollo Business and our new Chief Technology Officer, offset by reductions in the costs of depreciation and expensed materials and reagents.

We believe a substantial investment in research and development is essential in the long term to remain competitive and expand into additional markets. Accordingly, we expect our research and development expenses to remain at a high level of total expenditures for the foreseeable future.

General and Administrative

The following table presents general and administrative expenses for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
1,289,508
 
$
564,770
 
128%
   
$
2,101,043
 
$
1,225,418
 
71%

General and administrative expenses consist primarily of personnel costs for finance, human resources, business development, and general management, as well as professional fees, such as expenses for legal and accounting services.

For the three months ended June 30, 2014, general and administrative expenses increased $724,738, or 128%, as compared to the three months ended June 30, 2013. For the six months ended June 30, 2014, general and administrative expenses increased $875,625, or 71%, as compared to the six months ended June 30, 2013. The increase in both periods resulted primarily from recording a one-time, non-cash charge of approximately $600,000 related to stock options vesting over three years commencing on March 8, 2012, awarded to our Chief Executive Officer following our Annual Stockholders’ Meeting, and increases in consultancy costs.

Interest Income

The following table presents interest income for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
19
 
$
892
 
(98)%
   
$
27
 
$
2,087
 
(99)%


The interest income is solely earned on cash balances held in interest-bearing bank accounts.

For the three months ended June 30, 2014, interest income decreased by $873, or 98%, as compared to the three months ended June 30, 2013, and for the six months ended June 30, 2014, interest income decreased by $2,060, or 99%, as compared to the six months ended June 30, 2013. The decrease was mainly due to the absence of cash invested in interest-bearing accounts in Malaysia, with banks in the U.S. paying negligible interest in both periods.



Interest Expense

The following table presents interest expense for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
109,155
 
$
1,092,091
 
(90)%
   
$
212,482
 
$
1,972,629
 
(89)%

For the three months ended June 30, 2014, interest expense decreased $982,936, or 90%, as compared to the three months ended June 30, 2013. For the six months ended June 30, 2014, interest expense decreased $1,760,147, or 89%, as compared to the six months ended June 30, 2013. The decrease in both periods was due to the absence of charges for 5% interest and amortization of the debt discount and loan origination fees related to the convertible promissory notes (“CPNs”) in the aggregate principal amount of $15,275,000 issued in the May 2011 Private Placement and converted into equity securities on August 27, 2013. This decrease was offset by interest on the $5,200,000 in long-term debt issued to Malaysian Technology Development Corporation Sdn. Bhd. (“MTDC”), an investor in WaferGen Biosystems (M) Sdn. Bhd. (“WGBM”), our now-dissolved Malaysian subsidiary (the “MTDC Notes”), and on the IntegenX Note. Both are being amortized using the effective yield method, which weights the interest charges towards the latter stages of the contractual term of the debt. We expect that the 8% interest on the IntegenX Note, along with the amortization charges, will result in interest expense of approximately $450,000 in 2014, with increased expense in 2015 and subsequent years. However, if, prior to the maturity date of the IntegenX Note, we complete an equity offering in which we receive net proceeds of at least $15.0 million, we will be contractually required to repay the IntegenX Note early. Should this occur in the three months ending September 30, 2014, it would result in recording an immediate expense of approximately $140,000, offset by a reduction in future interest expense.

Gain (loss) on Revaluation of Derivative Liabilities, Net

The following table represents the gain (loss) on revaluation of derivative liabilities, net for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
1,158,240
 
$
115,237
 
905%
   
$
1,374,196
 
$
(478,480)
 
N/A

Our derivative liabilities arise due to the cash settlement provisions in certain warrants and unit warrants and the variable number of shares of our common stock that may be issued upon the exercise of those warrants with certain anti-dilution protection and, until the time of their settlement in 2013, upon the exchange of Series A and Series B Convertible Preference Shares (“CPS”) of WGBM, and under the conversion element of our CPNs.

The net gain from revaluation of derivative liabilities for the three months ended June 30, 2014, was $1,158,240, compared to a net gain of $115,237 for the three months ended June 30, 2013. The net gain from revaluation of derivative liabilities for the six months ended June 30, 2014, was $1,374,196, compared to a net loss of $478,480 for the six months ended June 30, 2013. Gains and losses are directly attributable to revaluations of all of our derivative liabilities and result primarily from a net decrease or increase, respectively, in our stock price in the period. Our closing stock price was $12.50 on June 30, 2014, compared to $20.00 on both March 31, 2014 and December 31, 2013, and was $39.76 on June 30, 2013, compared to $59.63 on March 31, 2013, and $29.82 on December 31, 2012. The gain in both 2014 periods and in the three months ended June 30, 2013, arose principally due to the decrease stock price in the three months ended June 30. The loss in the six months ended June 30, 2013, was caused principally by the increase in our stock price and by changes in estimated impact of future funding on our warrants with anti-dilution protection. With the present number of outstanding warrants accounted for as liabilities, at our closing stock price of $12.50 on June 30, 2014, an increase in our share price of $1.00 would generate a revaluation loss of approximately $80,000; conversely, a decrease in our share price of $1.00 would generate a revaluation gain of approximately $80,000.

Future gains or losses on revaluation will result primarily from net decreases or increases, respectively, in our stock price during the reporting period. Derivative liabilities will also decrease as the remaining term of each instrument diminishes.



Miscellaneous Income (Expense)

The following table presents miscellaneous income (expense) for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
(1,422)
 
$
79,621
 
N/A
   
$
(4,193)
 
$
67,343
 
N/A

For the three months ended June 30, 2014, we recorded miscellaneous expense of $1,422, compared to income of $79,621 for the three months ended June 30, 2013. For the six months ended June 30, 2014, we recorded miscellaneous expense of $4,193, compared to income of $67,343 for the six months ended June 30, 2013. Miscellaneous income or expense is the result of net foreign currency exchange gains or losses which, until it was dissolved in November 2013, arose mainly in WGBM, principally due to revaluation of the inter-company account at the balance sheet date. WGBM had a net receivable on its dollar denominated balances, so if the value of the Malaysian Ringgit decreased against the dollar, income was recorded, whereas if it increased against the dollar, an expense was recorded. Foreign currency exchange gains and losses also arise on our subsidiary in Luxembourg, and on U.S. expenses denominated in foreign currencies. Following the liquidation of WGBM, miscellaneous income and expense is not expected to be significant in future periods.

Provision for Income Taxes

The following table presents the provision for income taxes for the three and six months ended June 30, 2014 and 2013, respectively:

Three Months Ended June 30,
   
Six Months Ended June 30,
2014
 
2013
 
% Change
   
2014
 
2013
 
% Change
                               
$
 
$
(1,051)
 
N/A
   
$
3,100
 
$
2,661
 
16%

For the three months ended June 30, 2014, we recorded no income tax expense, compared to a credit of $1,051 for the three months ended June 30, 2013, for U.S. state income taxes. For the six months ended June 30, 2014 and 2013, we recorded a charge of $3,100 and $2,661, respectively, for U.S. state income taxes. We have provided a full valuation allowance against our net deferred tax assets.

Headcount

Our consolidated headcount as of August 12, 2014, comprised 42 regular employees, 41 of whom were employed full-time, compared to 28 regular employees as of December 31, 2013, all of whom were employed full-time.

Liquidity and Capital Resources

From inception through June 30, 2014, we have raised a total of $3,665,991 from the issuance of notes payable, $66,037 from the sale of Series A Preferred Stock, $1,559,942 from the sale of Series B Preferred Stock, $31,226,191, net of offering costs, from the sale of common stock and warrants, $8,842,256, net of offering costs, from the sale of CPS of our now-dissolved Malaysian subsidiary, $1,842,760, net of origination fees, from a secured term loan, and $27,492,876, net of offering costs and liquidated damages for late registration, from the sale of the Series A-1 Convertible Preferred Stock, convertible promissory notes and warrants in the May 2011 Private Placement, and $13,393,162, net of offering costs, from the sale of common stock, Series 1 Convertible Preferred Stock and warrants in the 2013 Private Placement. We also had, as of June 30, 2014, MTDC Notes with a principal amount of $5,200,000 and the IntegenX Note with a stated value of $1,298,611 outstanding. As of June 30, 2014, we had $3,521,549 in unrestricted cash and cash equivalents, and working capital of $3,231,026.

Net Cash Used in Operating Activities

We experienced negative cash flow from operating activities for the six months ended June 30, 2014 and 2013, in the amounts of $5,064,069 and $3,161,750, respectively. The cash used in operating activities in the six months ended June 30, 2014, was due to cash used to fund a net loss of $4,649,027, adjusted for non-cash expenses related to depreciation and amortization, stock-based compensation, net gains on revaluation of derivative liabilities, interest converted to principal on long-term debt, inventory provision and amortization of debt discount totaling $612,114, and cash provided by a change in working capital of $197,072. The cash used in operating activities in the six months ended June 30, 2013, was due to cash used to fund a net loss of $6,944,665, adjusted for non-cash expenses related to depreciation and amortization, stock-based compensation, net losses on revaluation of derivative liabilities, interest


converted to principal on convertible promissory notes, inventory provision and amortization of debt discount totaling $2,964,913, and cash provided by a change in working capital of $818,002. The increase in cash used in the six months ended June 30, 2014, compared to 2013, was driven primarily by the increase in the net operating loss from $4,560,325 to $5,803,475, and the cash not yet provided by the increase in accounts receivable.

Net Cash Used in Investing Activities

We used $123,028 in the six months ended June 30, 2014, and $34,347 in the six months ended June 30, 2013, to acquire property and equipment. Further, in the six months ended June 30, 2014, we used $2,000,000 to acquire the Apollo Business.

Net Cash Provided by Financing Activities

There were no financing activities in the six months ended June 30, 2014 or 2013.

Availability of Additional Funds

We believe funds available at June 30, 2014, along with our revenue, are sufficient to fund our operations into the fourth quarter of 2014. To continue our operations thereafter, we expect we will need to raise further capital, through the sale of additional securities or otherwise. Our operating needs include the planned costs to operate our business, including amounts required to fund working capital and capital expenditures. At the present time, we have no material commitments for capital expenditure. Our future capital requirements and the adequacy of our available funds will depend on many factors, most notably our ability to successfully commercialize our SmartChip products and services.

While we believe we have sufficient cash to fund our operating, investing and financing activities into the fourth quarter of 2014, we expect that additional working capital will be needed to sustain our operations and to repay our outstanding debt obligations thereafter. We are currently exploring various possible financing options that may be available to us, which may include a sale of our equity securities. We have no commitments to obtain any additional funds and there can be no assurance that we will be able to raise sufficient additional capital when we need it on favorable terms, or at all. The conversion of our MTDC Notes, and the sale of equity or convertible debt securities in the future, may be dilutive to our stockholders, and debt financing arrangements may require us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further indebtedness, and may contain other terms that are not favorable to us or our stockholders. If we are unable to obtain needed capital we may not be able to continue our efforts to develop and commercialize our SmartChip products and services and may be forced to significantly curtail or suspend our operations.

Principles of Consolidation

The consolidated financial statements of WaferGen Bio-systems, Inc. include the accounts of Wafergen, Inc., WaferGen Biosystems Europe S.a.r.l., our Luxembourg subsidiary and, prior to its liquidation, WaferGen Biosystems (M) Sdn. Bhd., our Malaysian subsidiary. All significant inter-company transactions and balances are eliminated in consolidation.

Critical Accounting Policies and Estimates

Deferred Tax Valuation Allowance

We believe sufficient uncertainties exist regarding the future realization of deferred tax assets, and, accordingly, a full valuation allowance is required, amounting to approximately $30,000,000 at December 31, 2013. In subsequent periods, if and when we generate pre-tax income, a tax expense will not be recorded to the extent that the remaining valuation allowance can be used to offset that expense. Once a consistent pattern of pre-tax income is established or other events occur that indicate that the deferred tax assets will be realized, additional portions or all of the remaining valuation allowance will be reversed back to income. Should we generate pre-tax losses in subsequent periods, a tax benefit will not be recorded and the valuation allowance will be increased.

Inventory Valuation

Inventories are stated at the lower of cost and market value. We perform a detailed assessment of inventory on a regular basis, which includes, among other factors, a review of projected demand requirements, product pricing, product expiration and product lifecycle. As a result of this assessment, we record provisions for potentially excess, obsolete or impaired goods, when appropriate, in order to reduce the reported amount of inventory to its net realizable value. If actual demand and market conditions are less favorable than those projected by management, additional inventory write-downs may be required.


Warranty Reserve

Our standard warranty agreement is one year from shipment for SmartChip cyclers and dispensers and Apollo systems. We accrue for anticipated warranty costs upon shipment of these products. Our warranty reserve is based on management’s judgment regarding anticipated rates of warranty claims and associated repair costs, and we update our assessment quarterly.

Stock-Based Compensation

We measure the fair value of all stock option and restricted stock awards to employees on the grant date, and record the fair value of these awards, net of estimated forfeitures, as compensation expense over the service period. The fair value of options is estimated using the Black-Scholes valuation model, and for restricted stock it is based on our closing share price on the measurement date. Amounts expensed with respect to options were $697,297 and $182,701, net of estimated forfeitures, for the six months ended June 30, 2014 and 2013, respectively. These sums exclude the compensation expense for restricted stock awards, for which the fair value is based on our closing stock price on the grant date for directors and employees, and on the dates on which performance of services is recognized for consultants.

The weighted average grant date fair value of options awarded in the six months ended June 30, 2014 and 2013, was $9.86 and $37.24, respectively. Fair values were estimated using the following assumptions:

 
Six Months Ended June 30,
 
 
2014
 
2013
 
         
Risk-free interest rate
1.43%
 
0.71%
 
Expected term
4.75 Years
 
4.75 Years
 
Expected volatility
93.89%
 
108.14%
 
Dividend yield
0%
 
0%
 

Risk-Free Interest Rate.  This is the U.S. Treasury rate for the day of the grant having a term equal to the expected term of the option. An increase in the risk-free interest rate will increase the fair value and the related compensation expense.

Expected Term.  This is the period of time over which the award is expected to remain outstanding and is based on management’s estimate, taking into consideration the vesting terms, the contractual life, and historical experience. An increase in the expected term will increase the fair value and the related compensation expense.

Expected Volatility.  This is a measure of the amount by which our common stock price has fluctuated or is expected to fluctuate. We apply 50% weighting to our own historic volatility and 50% to the historic volatility of a group of publicly traded companies over the retrospective period corresponding to the expected term of the options on the measurement date. Since the 2013 Exchange, we have applied a reduced weighting to our own historic volatility during the period in which we were highly leveraged. The group of publicly traded companies is selected from the same industry or market index, with extra weighting attached to those companies most similar in terms of business activity, size and financial leverage. An increase in the expected volatility will increase the fair value and the related compensation expense.

Dividend Yield.  We have not made any dividend payments and do not plan to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value and the related compensation expense.

Forfeiture Rate.  This is a measure of the amount of awards that are expected to not vest. An increase in the estimated forfeiture rate will decrease the related compensation expense.

Derivative Liabilities

Our derivative liabilities arise due to the cash settlement provisions in certain warrants and unit warrants and the variable number of shares of our common stock that may be issued upon the exercise of those warrants with certain anti-dilution protection and, until the time of their settlement in 2013, upon the exchange of Series A and Series B CPS of our Malaysian subsidiary, and under the conversion element of our CPNs. We evaluate the liability for those warrants for which no anti-dilution adjustment is projected prior to the expiration date using the Black-Scholes valuation model, and all other derivatives using a Monte Carlo Simulation approach, using critical assumptions provided by management reflecting conditions at the valuation dates.



Our derivatives are revalued at each balance sheet date, and at the time of issuance and settlement, and are estimated using the following assumptions:

Risk-Free Interest Rate.  This is the U.S. Treasury rate for the measurement date having a term equal to the weighted average expected remaining term of the instrument. An increase in the risk-free interest rate will increase the fair value and the associated derivative liability.

Expected Remaining Term.  This is the period of time over which the instrument is expected to remain outstanding and is based on management’s estimate, taking into consideration the remaining contractual life, historical experience and the possibility of liquidation. An increase in the expected remaining term will increase the fair value and the associated derivative liability.

Expected Volatility.  This is a measure of the amount by which our common stock price has fluctuated or is expected to fluctuate. We apply 50% weighting to our own historic volatility and 50% to the historic volatility of a group of publicly traded companies over the retrospective period corresponding to the expected remaining term of the instrument on the measurement date. Since the 2013 Exchange, the Company has applied a reduced weighting to its own historic volatility during the period in which it was highly leveraged. The group of publicly traded companies is selected from the same industry or market index, with extra weighting attached to those companies most similar in terms of business activity, size and financial leverage. An increase in the expected volatility will increase the fair value and the associated derivative liability.

Dividend Yield.  We have not made any dividend payments and do not plan to pay dividends in the foreseeable future. An increase in the dividend yield will decrease the fair value and the associated derivative liability.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, result of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Recent Accounting Pronouncements

See the “Recent Accounting Pronouncements” in Note 2 to the Condensed Consolidated Financial Statements in Part I, Item 1 for information related to the adoption of new accounting standards in the first six months of 2014, none of which had a material impact on our condensed consolidated financial statements.


Item 4.  Controls and Procedures

Management’s Report on Internal Control over Financial Reporting

As of the end of the period covered by this Quarterly Report, management performed, with the participation of our principal executive officer and principal financial officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the report we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s forms, and that such information is accumulated and communicated to our management including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive officer and principal financial officer concluded that, as of June 30, 2014, the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2014, we designed and implemented procedures to address the following material weaknesses:

 
1)
We had not designed or otherwise maintained adequate controls to ensure that we identify all of the clauses in warrant agreements which could cause such warrants to require liability classification; and

 
2)
There was an operating deficiency in the calculation of the weighted average number of shares outstanding in a manual spreadsheet, and in the subsequent review process, which failed to detect and correct the error.


Both of these material weaknesses were originally reported in our Quarterly Report on Form 10-Q/A for the period ended September 30, 2013, filed with the SEC on February 12, 2014.

During the quarter ended June 30, 2014, we assessed that these procedures have been operating effectively for a sufficient period to enable us to conclude that both of these material weaknesses have been remediated.

Other than the implementation of these new procedures, there was no material change in the Company’s internal control over financial reporting that occurred during the quarter ended June 30, 2014, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.




PART II OTHER INFORMATION


Item 1.  Legal Proceedings

From time to time we may be involved in claims arising in connection with our business. Based on information currently available, we believe that the amount, or range, of reasonably possible losses in connection with any pending actions against us, in excess of established reserves, in the aggregate, not to be material to our consolidated financial condition or cash flows. However, losses may be material to our operating results for any particular future period, depending on the level of income for such period.

Coalesce v. WaferGen.  On April 24, 2012, an action entitled Coalesce Corporation (“Coalesce”) v. WaferGen Bio-systems, Inc. was filed in the Alameda County Superior Court. Coalesce, a company that had been providing marketing services between 2006 and 2010, sued us for alleged non-payment of sums due, breach of contract, misrepresentation and unjust enrichment. On September 5, 2012, Coalesce filed an amended complaint, with additional claims, for compensatory damages in excess of $500,000 and other compensation. In August 2014, we agreed to an out-of-court settlement with the plaintiff, with certain details to be finalized in a formal written agreement. We recorded an expense of $110,000 in the three months ended June 30, 2014, to increase the sum accrued to the amount of the out-of-court settlement.


Item 1A.  Risk Factors

You should consider the risks and uncertainties described under Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which we filed with the Securities and Exchange Commission on March 14, 2014, together with all other information contained or incorporated by reference in this Quarterly Report on Form 10-Q when evaluating our business and our prospects. There are no material changes from the risk factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013.


Item 6.  Exhibits

The exhibits required to be filed as a part of this report are listed in the Exhibit Index.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


   
WAFERGEN BIO-SYSTEMS, INC.
     
Dated: August 14, 2014
   
     
   
By:  /s/ STEPHEN BAKER
 
   
Stephen Baker
   
Chief Financial Officer
   
(principal financial officer)




EXHIBIT INDEX
Exhibit
   
Number
 
Description
     
3.1
 
Certificate of Amendment to the Amended and Restated Articles of Incorporation of the Company (incorporated by reference to Exhibit 3 to the Current Report on Form 8-K filed on June 30, 2014)
     
10.1
 
Amendment to the WaferGen Bio-systems, Inc. 2008 Stock Incentive Plan (incorporated by reference to Appendix B to the Proxy Statement on Form PRE-14A filed on April 6, 2014)
     
10.2
 
Amendment dated as of June 27, 2014, to Lease Agreement by and between Wafergen, Inc. and LBA Realty Fund III-Company VII, LLC dated October 22, 2009 (incorporated by reference to Exhibit 10.17 to the Registration Statement on Form S-1 filed on July 18, 2014)
     
10.3
 
Irrevocable Waiver of Board Rights Under Exchange Agreement dated as of August 27, 2013 by and among WaferGen Bio-systems, Inc. and the investors listed on the signature pages thereto (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1 filed on July 18, 2014)
     
31.1
 
Rule 13a-14(a)/15d-15(e) Certification of principal executive officer
     
31.2
 
Rule 13a-14(a)/15d-15(e) Certification of principal financial officer
     
32.1
 
Section 1350 Certification of principal executive officer
     
32.2
 
Section 1350 Certification of principal financial officer
     
101 §
 
The following financial information from the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014, formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets at June 30, 2014 and December 31, 2013, (ii) the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2014 and 2013, (iii) the Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2014 and 2013, and (iv) Notes to the Condensed Consolidated Financial Statements.

     
§
 
 
Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filings.

 
33